Balancing Potential and Uncertainty: Hold Rating on Amylyx Pharmaceuticals Post-Avexitide Acquisition
Analyst Ratings For Amylyx Pharma
Analysts' ratings for Amylyx Pharma (NASDAQ:AMLX) over the last quarter vary from bullish to bearish, as provided by 5 analysts.The following table summarizes their recent ratings, shedding light on
NVIDIA To Rally More Than 33%? Here Are 10 Top Analyst Forecasts For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.Piper
Express News | Goldman Sachs Maintains Neutral on Amylyx Pharma, Raises Price Target to $4
Mizuho Securities Maintains Amylyx Pharmaceuticals(AMLX.US) With Hold Rating
Mizuho Securities analyst Graig Suvannavejh maintains $Amylyx Pharmaceuticals(AMLX.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 46.2% and a total average
Amylyx Pharmaceuticals: Holding Steady Amidst Expansion and Market Skepticism
Goldman Sachs Maintains Amylyx Pharmaceuticals(AMLX.US) With Hold Rating, Announces Target Price $4
Goldman Sachs analyst Corinne Johnson maintains $Amylyx Pharmaceuticals(AMLX.US)$ with a hold rating, and sets the target price at $4.According to TipRanks data, the analyst has a success rate of 55.7
Analysts Conflicted on These Healthcare Names: Amylyx Pharmaceuticals Inc (AMLX), Centene (CNC) and Radnet (RDNT)
BofA Securities Initiates Amylyx Pharmaceuticals(AMLX.US) With Hold Rating, Announces Target Price $3.5
BofA Securities analyst Charlie CY Yang initiates coverage on $Amylyx Pharmaceuticals(AMLX.US)$ with a hold rating, and sets the target price at $3.5.According to TipRanks data, the analyst has a
Analysts Offer Insights on Healthcare Companies: Becton Dickinson (BDX), Teladoc (TDOC) and Amylyx Pharmaceuticals Inc (AMLX)
Why Is Small Cap Amylyx Pharmaceuticals Stock Trading Higher On Wednesday?
Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) acquired avexitide from Eiger BioPharmaceuticals Inc (OTC:EIGRQ) for $35.1 million.Avexitide is an investigational, first-in-class glucagon-like peptide-1 (
Amylyx Jumps on Acquisition of Eiger's GLP-1 Drug
Amylyx Pharmaceuticals, Inc. (AMLX) Avexitide Acquisition Conference Call Transcript
Amylyx Pharmaceuticals, Inc. (AMLX) Avexitide Acquisition Conference Call Transcript
Express News | Amylyx Pharmaceuticals Shares Are Trading Higher After the Company Announced That It Acquired Avexitide From Eiger BioPharmaceuticals
Amylyx Pharmaceuticals Price Target Maintained With a $8.00/Share by HC Wainwright & Co.
Amylyx Pharmaceuticals Price Target Maintained With a $8.00/Share by HC Wainwright & Co.
Amylyx Pharmaceuticals Inc: Strong Buy Rating on Avexitide's Potential and Strategic Pipeline Expansion
Express News | Eiger BioPharmaceuticals Inc - Sale of Co's Avexitide Asset Closed on July 9
Express News | Amylyx Pharmaceuticals Shares up 8.5% Premarket After Completing Acquisition of Experimental Low Blood Sugar Drug
Express News | Amylyx Pharmaceuticals Acquired Avexitide From Eiger Biopharmaceuticals, For The Potential Treatment Of Hyper Insulinemic Hypoglycemia For $35.1M
Express News | Amylyx Pharmaceuticals: Engaging in Talks With Broader Congenital Hi Community to Develop Path Forward Based on Promising Phase 2 Study Results